Skip to main content
Luoxin Pharmaceuticals Group Stock Co., Ltd. logo

Luoxin Pharmaceuticals Group Stock Co., Ltd. — Investor Relations & Filings

Ticker · 002793 ISIN · CNE1000026S7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,601 across all filing types
Latest filing 2026-05-28 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 002793

About Luoxin Pharmaceuticals Group Stock Co., Ltd.

https://www.luoxin.cn

Luoxin Pharmaceuticals Group Stock Co., Ltd. focuses on the research, development, manufacturing, and distribution of diverse medicinal products. The company specializes in therapeutic areas including digestive health, respiratory medicine, anti-infectives, and oncology. Its portfolio includes various formulations such as injections, tablets, and capsules, with a notable emphasis on proton pump inhibitors and respiratory treatments. Luoxin operates a vertically integrated model, producing both active pharmaceutical ingredients (APIs) and finished dosage forms. The organization emphasizes innovation through dedicated R&D facilities to develop high-quality healthcare solutions. Its operations are supported by a comprehensive supply chain and manufacturing infrastructure designed to adhere to international quality standards, serving broad market segments with a focus on clinical efficacy and patient accessibility.

Recent filings

Filing Released Lang Actions
北京市金杜律师事务所上海分所关于罗欣药业集团股份有限公司2026年第三次临时股东会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a legal opinion letter issued by counsel regarding the company’s 2026 third extraordinary shareholders’ meeting, containing detailed vote counts for each resolution and certifying the legality of the convening, attendance, and voting procedures. It is not merely an announcement of a report, nor is it standalone litigation or management report. As it is an official record of shareholder voting results at an EGM, it best fits the Declaration of Voting Results & Voting Rights category (DVA).
2026-05-28 Chinese
2026年第三次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an official announcement of the resolutions and detailed voting results from the company’s third extraordinary shareholders’ meeting, including vote counts for each proposal and legal opinion confirmation. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-28 Chinese
关于控股子公司的产品注射用阿奇霉素情况说明的公告
Legal Proceedings Report Classification · 91% confidence The document is a voluntary company announcement detailing an administrative penalty imposed by the Shandong Provincial Drug Supervision Administration on the company’s subsidiary, including background of the event, penalty details, investigation findings and remediation measures. This is a regulatory action rather than a financial report or board change, fitting the definition for Legal Proceedings Report (LTR): updates on significant lawsuits or regulatory actions involving the company.
2026-05-20 Chinese
关于转让控股子公司股权的进展公告
M&A Activity Classification · 87% confidence The document is a corporate announcement by a listed company regarding the progress of transferring its 70% controlling equity stake in a subsidiary, detailing payment schedules, performance commitment fulfilment, and next steps. This describes a divestiture transaction (asset sale) rather than financial results, regulatory filings, or board changes. Under our taxonomy, disposal of a controlling subsidiary stake falls under M&A Activity.
2026-05-20 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement detailing the resolutions passed at the company’s 2025 annual shareholders’ meeting, including vote counts and percentages for each proposal. It does not present financial statements or broader report content but specifically declares voting outcomes. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2026-05-18 Chinese
北京市金杜律师事务所上海分所关于罗欣药业集团股份有限公司2025年年度股东会之法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter (法律意见书) issued by King & Wood law firm regarding the convening, procedures, attendance, and voting results of the company’s 2025 Annual General Meeting held on May 18, 2026. It is not the AGM materials (presentation), not the formal vote results announcement by the company (which would be a pure DVA), nor does it fit other specific financial or governance report categories. It is a compliance/legal document to be filed, so it falls under the fallback “Regulatory Filings (RNS).”
2026-05-18 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.